NCT01113294

Brief Summary

To compare the efficacy of different procedures, identify the optimal procedure, ablation sites, ablation endpoints and post-operative anticoagulation strategy, establish the optimal treatment strategy for atrial fibrillation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,040

participants targeted

Target at P75+ for phase_4 atrial-fibrillation

Timeline
Completed

Started Jan 2009

Longer than P75 for phase_4 atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

April 21, 2010

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 29, 2010

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

April 29, 2010

Status Verified

January 1, 2009

Enrollment Period

3.9 years

First QC Date

April 21, 2010

Last Update Submit

April 27, 2010

Conditions

Outcome Measures

Primary Outcomes (4)

  • recurrence of atrial arrhythmias (AF, AFL, AT)

    1 month

  • recurrence of atrial arrhythmias (AF, AFL, AT)

    3 month

  • recurrence of atrial arrhythmias (AF, AFL, AT)

    6 month

  • recurrence of atrial arrhythmias (AF, AFL, AT)

    12 month

Secondary Outcomes (16)

  • Number of participants with all-cause death

    1 month

  • Number of participants with all-cause death

    3 month

  • Number of participants with all-cause death

    6 month

  • Number of participants with all-cause death

    12 month

  • severe blooding complications

    1 month

  • +11 more secondary outcomes

Study Arms (1)

ablation

EXPERIMENTAL
Procedure: catheter ablation

Interventions

circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation

ablation

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Atrial fibrillation recorded by ECG or Holter;
  • Age: 18 \~ 75 years;
  • Patients who are willing to enroll in the trial

You may not qualify if:

  • Patients accompanied hyperthyroidism;
  • Patients with sever liver or renal dysfunction;
  • Patients with sever cardiac dysfunction;
  • Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure;
  • Patients with emboli in atrium;
  • Pregnant woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Renmin Hospital of Wuhan University

Wuhan, Hubei, 430060, China

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Catheter Ablation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Radiofrequency AblationRadiofrequency TherapyTherapeuticsAblation TechniquesSurgical Procedures, Operative

Study Officials

  • Cong-xin Huang, doctor

    Renmin Hospital of Wuhan University

    STUDY CHAIR

Central Study Contacts

Cong-xin Huang, doctor

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 21, 2010

First Posted

April 29, 2010

Study Start

January 1, 2009

Primary Completion

December 1, 2012

Study Completion

December 1, 2013

Last Updated

April 29, 2010

Record last verified: 2009-01

Locations